New COPD Candidates Could Get Hung Up On Safety Concerns
FDA is facing several novel candidates for chronic obstructive pulmonary disease in 2013; those products should expect close scrutiny due to past issues with class safety and new signals in clinical trials.
You may also be interested in...
Aquinox Pulls In $18M In Venture Funds As COPD Drug Moves Forward
The Canadian company will use the funds from its Series C financing to advance its lead drug candidate through Phase II testing in two indications, including COPD.
GSK’s Breo Ellipta Gets “Snowquestered” As FDA Delays Advisory Cmte
FDA missed its deadline to post the advisory committee briefing materials then postponed the meeting as a winter storm headed towards Washington.
Business News, In Brief
Quintiles files IPO; Forest sees LAMA/LABA combo product, slated for a 2014 NDA, as filling out a suite of COPD drugs to cover the full range of disease severity. Plus news from a host of biopharma quarterly earnings calls.